ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Raises Dividend to $0.18 Per Share

Key Points

• ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) has announced a quarterly dividend increase to $0.18 per share, marking a 5.8% rise from the previous dividend of $0.17.
• Shareholders on record by September 24th will receive the dividend payment on September 30th, with an ex-dividend date of September 24th.
• The current market capitalization of BIB is $58.70 million, and the stock opened at $58.12, showing a decline of 0.9% in trading.

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) declared a quarterly dividend on Tuesday, September 23rd. Shareholders of record on Wednesday, September 24th will be paid a dividend of 0.1805 per share by the exchange traded fund on Tuesday, September 30th. This represents a c) dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 24th. This is a 5.8% increase from ProShares Ultra Nasdaq Biotechnology's previous quarterly dividend of $0.17.

ProShares Ultra Nasdaq Biotechnology Trading Down 0.9%

NASDAQ BIB opened at $58.12 on Wednesday. The business's 50-day moving average price is $54.47 and its 200 day moving average price is $48.86. ProShares Ultra Nasdaq Biotechnology has a twelve month low of $33.78 and a twelve month high of $68.00. The company has a market capitalization of $58.70 million, a PE ratio of 20.68 and a beta of 1.63.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.